A detailed history of Jacobs Levy Equity Management, Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,355,002 shares of ACAD stock, worth $20 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,355,002
Holding current value
$20 Million
% of portfolio
0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $19.8 Million - $25 Million
1,355,002 New
1,355,002 $22 Million
Q4 2023

Feb 14, 2024

SELL
$20.78 - $31.77 $27.4 Million - $41.9 Million
-1,319,007 Reduced 92.6%
105,396 $3.3 Million
Q3 2023

Nov 16, 2023

SELL
$20.84 - $33.47 $8.58 Million - $13.8 Million
-411,615 Reduced 22.42%
1,424,403 $29.7 Million
Q2 2023

Aug 14, 2023

SELL
$17.8 - $25.65 $824,763 - $1.19 Million
-46,335 Reduced 2.46%
1,836,018 $44 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $3.97 Million - $5.09 Million
243,170 Added 14.83%
1,882,353 $35.4 Million
Q4 2022

Feb 14, 2023

BUY
$14.2 - $18.63 $7.85 Million - $10.3 Million
552,681 Added 50.87%
1,639,183 $26.1 Million
Q3 2022

Nov 15, 2022

BUY
$14.11 - $18.27 $15.3 Million - $19.9 Million
1,086,502 New
1,086,502 $17.8 Million
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $7.67 Million - $16.1 Million
-589,726 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$20.94 - $27.5 $1.02 Million - $1.34 Million
48,664 Added 8.99%
589,726 $14.3 Million
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $517,702 - $835,293
30,834 Added 6.04%
541,062 $12.6 Million
Q3 2021

Nov 15, 2021

BUY
$15.78 - $24.77 $8.05 Million - $12.6 Million
510,228 New
510,228 $8.48 Million
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $365,593 - $516,729
-18,845 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $471,501 - $1.04 Million
18,845 New
18,845 $486,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.